These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 25316819

  • 1. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.
    Ravi D, Bhalla S, Gartenhaus RB, Crombie J, Kandela I, Sharma J, Mazar A, Evens AM.
    Clin Cancer Res; 2014 Dec 01; 20(23):6023-33. PubMed ID: 25316819
    [Abstract] [Full Text] [Related]

  • 2. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line.
    Matulis SM, Morales AA, Yehiayan L, Croutch C, Gutman D, Cai Y, Lee KP, Boise LH.
    Mol Cancer Ther; 2009 May 01; 8(5):1197-206. PubMed ID: 19417148
    [Abstract] [Full Text] [Related]

  • 3. Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer.
    Tian J, Zhao H, Nolley R, Reese SW, Young SR, Li X, Peehl DM, Knox SJ.
    Clin Cancer Res; 2012 Jun 15; 18(12):3366-76. PubMed ID: 22535156
    [Abstract] [Full Text] [Related]

  • 4. A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines.
    Diaz Z, Mann KK, Marcoux S, Kourelis M, Colombo M, Komarnitsky PB, Miller WH.
    Leukemia; 2008 Oct 15; 22(10):1853-63. PubMed ID: 18633430
    [Abstract] [Full Text] [Related]

  • 5. Darinaparsin: a novel organic arsenical with promising anticancer activity.
    Mann KK, Wallner B, Lossos IS, Miller WH.
    Expert Opin Investig Drugs; 2009 Nov 15; 18(11):1727-34. PubMed ID: 19780704
    [Abstract] [Full Text] [Related]

  • 6. Combinatorial ixazomib and belinostat therapy induces NFE2L2-dependent apoptosis in Hodgkin and T-cell lymphoma.
    Passero FC, Ravi D, McDonald JT, Beheshti A, David KA, Evens AM.
    Br J Haematol; 2020 Jan 15; 188(2):295-308. PubMed ID: 31452195
    [Abstract] [Full Text] [Related]

  • 7. Proteasomal Inhibition by Ixazomib Induces CHK1 and MYC-Dependent Cell Death in T-cell and Hodgkin Lymphoma.
    Ravi D, Beheshti A, Abermil N, Passero F, Sharma J, Coyle M, Kritharis A, Kandela I, Hlatky L, Sitkovsky MV, Mazar A, Gartenhaus RB, Evens AM.
    Cancer Res; 2016 Jun 01; 76(11):3319-31. PubMed ID: 26988986
    [Abstract] [Full Text] [Related]

  • 8. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
    Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, Carlo-Stella C.
    Leukemia; 2013 Aug 01; 27(8):1677-87. PubMed ID: 23360848
    [Abstract] [Full Text] [Related]

  • 9. Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of hedgehog signaling.
    Bansal N, Farley NJ, Wu L, Lewis J, Youssoufian H, Bertino JR.
    Mol Cancer Ther; 2015 Jan 01; 14(1):23-30. PubMed ID: 25381261
    [Abstract] [Full Text] [Related]

  • 10. Effects of arsenic trioxide under different administration ways on T-cell lymphoma xenografts in nude mice: in vivo and in vitro experiments.
    Gao Y, Cai QQ, Li S, Bu Q, Liao H, Zhou Y, Huang HQ.
    Ai Zheng; 2009 Feb 01; 28(2):127-31. PubMed ID: 19550119
    [Abstract] [Full Text] [Related]

  • 11. [Pharmacological profile and clinical study results of darinaparsin (DARVIAS® injection 135 ‍mg), an organic arsenic product, for relapsed or refractory peripheral t-cell lymphoma].
    Yao K, Sonehara Y, Nagahama F.
    Nihon Yakurigaku Zasshi; 2023 Feb 01; 158(5):408-418. PubMed ID: 37673618
    [Abstract] [Full Text] [Related]

  • 12. Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin.
    Chiu HW, Ho YS, Wang YJ.
    J Mol Med (Berl); 2011 Sep 01; 89(9):927-41. PubMed ID: 21594580
    [Abstract] [Full Text] [Related]

  • 13. Cytotoxic Effects of Darinaparsin, a Novel Organic Arsenical, against Human Leukemia Cells.
    Yuan B, Kikuchi H, Li J, Kawabata A, Yao K, Takagi N, Okazaki M.
    Int J Mol Sci; 2023 Jan 23; 24(3):. PubMed ID: 36768603
    [Abstract] [Full Text] [Related]

  • 14. Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.
    Locatelli SL, Careddu G, Stirparo GG, Castagna L, Santoro A, Carlo-Stella C.
    Sci Rep; 2016 Oct 21; 6():35745. PubMed ID: 27767172
    [Abstract] [Full Text] [Related]

  • 15. Quercetin induces mitochondrial-derived apoptosis via reactive oxygen species-mediated ERK activation in HL-60 leukemia cells and xenograft.
    Lee WJ, Hsiao M, Chang JL, Yang SF, Tseng TH, Cheng CW, Chow JM, Lin KH, Lin YW, Liu CC, Lee LM, Chien MH.
    Arch Toxicol; 2015 Jul 21; 89(7):1103-17. PubMed ID: 25138434
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A.
    Clin Cancer Res; 2006 Jan 15; 12(2):584-90. PubMed ID: 16428504
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma.
    Sasi BK, Martines C, Xerxa E, Porro F, Kalkan H, Fazio R, Turkalj S, Bojnik E, Pyrzynska B, Stachura J, Zerrouqi A, Bobrowicz M, Winiarska M, Priebe V, Bertoni F, Mansouri L, Rosenquist R, Efremov DG.
    Leukemia; 2019 Oct 15; 33(10):2416-2428. PubMed ID: 30872780
    [Abstract] [Full Text] [Related]

  • 18. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M, Kasprzycka M, Liu X, El-Salem M, Halasa K, Raghunath PN, Bucki R, Wlodarski P, Wasik MA.
    Oncogene; 2007 Aug 16; 26(38):5606-14. PubMed ID: 17353907
    [Abstract] [Full Text] [Related]

  • 19. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
    Nagy N, Hajdu M, Márk Á, Király PA, Tóth M, Dankó T, Csóka M, Sebestyén A.
    Tumour Biol; 2016 Oct 16; 37(10):13695-13704. PubMed ID: 27473087
    [Abstract] [Full Text] [Related]

  • 20. Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea.
    Ogura M, Kim WS, Uchida T, Uike N, Suehiro Y, Ishizawa K, Nagai H, Nagahama F, Sonehara Y, Tobinai K.
    Jpn J Clin Oncol; 2021 Feb 08; 51(2):218-227. PubMed ID: 33051668
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.